STOCK TITAN

Qualigen Therapeutics, Inc. - QLGN STOCK NEWS

Welcome to our dedicated page for Qualigen Therapeutics news (Ticker: QLGN), a resource for investors and traders seeking the latest updates and insights on Qualigen Therapeutics stock.

Qualigen Therapeutics, Inc. (symbol: QLGN) is an early-clinical-stage therapeutics company dedicated to the development of innovative treatments for both adult and pediatric cancer. Headquartered in Carlsbad, California, the company's core focus lies in its pioneering research to tackle malignant diseases through its advanced therapeutic programs.

Core Business:
Qualigen's primary business activity revolves around its two key therapeutic programs. The flagship program, QN-302, is an investigational small molecule that acts as a G-quadruplexes (G4)-selective transcription inhibitor. This molecule exhibits a strong binding affinity to G4 structures prevalent in cancer cells, making it a potent candidate in cancer therapy. Additionally, Qualigen has another promising preclinical therapeutic program in its pipeline.

Recent Achievements:

  • Recently, Qualigen transitioned from a preclinical to a clinical-stage company following the Investigational New Drug (IND) clearance for QN-302. This milestone marks a significant progression in clinical development and potential cancer treatment breakthroughs.
  • The company also divested its FastPack® diagnostics business for approximately $5 million in an all-cash transaction. This strategic move enables Qualigen to concentrate resources on advancing its therapeutics pipeline.

Current Projects:
The ongoing development of QN-302 is a testament to Qualigen's commitment to pioneering cancer treatment solutions. The company is actively engaged in early-phase clinical trials to validate the efficacy and safety of QN-302 and other pipeline candidates.

Financial Condition:
The financial stability of Qualigen is bolstered by the sale proceeds from the divested diagnostics business, providing the necessary capital to fund ongoing and future therapeutic projects. Continuous investments in research and development underscore the company's dedication to discovering and developing novel cancer therapies.

Partnerships:
Qualigen collaborates with various research institutions and industry leaders to advance its drug development initiatives. These partnerships are crucial for fostering innovation and expediting the therapeutic development process.

For more information about Qualigen Therapeutics, Inc., please visit www.qlgntx.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.3%
Tags
none
-
Rhea-AI Summary

Qualigen Therapeutics reported that it received a notification from Nasdaq regarding its failure to file the Annual Report on Form 10-K for the year ending December 31, 2022, as mandated by Nasdaq Rules. The delay in the filing, due to additional information required for the company’s acquisition of a majority interest in NanoSynex, Ltd, resulted in the company filing a Notification of Late Filing on Form 12b-25. While this notification does not immediately affect the Nasdaq listing, failure to regain compliance may lead to delisting. Qualigen is working to file the Form 10-K by June 20, 2023, which would help avoid submitting a formal compliance plan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.65%
Tags
none
Rhea-AI Summary

Qualigen Therapeutics (Nasdaq: QLGN) announced significant findings from its QN-302 program presented at the AACR Annual Meeting 2023. The data highlighted QN-302's potential as a treatment for pancreatic cancer, showing 10-fold greater potency compared to existing therapies like gemcitabine in resistant cell lines. Doctor Tariq Arshad stated that these results support their goal to submit an IND application to the FDA to initiate Phase 1 trials for QN-302. The research demonstrated that QN-302 targets the S100P gene, a promising biomarker for therapy tracking, and confirmed anti-tumor activity in various in vivo models.

QN-302 has already been granted Orphan Drug Designation by the FDA, underlining its potential as a novel treatment strategy against cancers characterized by G4 structures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.47%
Tags
none
-
Rhea-AI Summary

Qualigen Therapeutics (Nasdaq: QLGN) has presented promising in vivo efficacy data regarding its QN-247 program at the American Association for Cancer Research (AACR) Annual Meeting 2023. This data suggests that QN-247 could serve as an effective nano-immunotherapy against triple negative breast cancer. The study showed significant reductions in tumor volumes without toxic side effects.

QN-247, a nucleolin-targeted oligonucleotide conjugate, demonstrates potential against various malignancies, including acute myeloid leukemia and glioblastoma. The company is actively seeking partners to advance the development of QN-247. Qualigen's broader portfolio includes diagnostics and other investigational compounds targeting different cancer types.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.47%
Tags
none
-
Rhea-AI Summary

Qualigen Therapeutics announces the grant of U.S. Patent No. 11,560,380 for its lead oncology drug candidate, QN-302. This patent protects the composition of matter for QN-302, a small molecule selective transcription inhibitor targeting G4 complexes in solid tumors, including pancreatic cancer, with exclusivity until 2040. The company also received a Notice of Intent for a similar patent in the E.U. CEO Michael Poirier emphasized the importance of this patent for QN-302's development, and the company is preparing to submit an Investigational New Drug (IND) application soon. QN-302 has already received Orphan Drug Designation from the FDA for pancreatic cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.33%
Tags
none
Rhea-AI Summary

Qualigen Therapeutics (Nasdaq: QLGN) announces participation at the AACR Annual Meeting 2023 in Orlando, FL, held from April 14-19. The company will present five posters, highlighting their lead program QN-302 and a study on QN-247 in Triple Negative Breast Cancer. Key presentations include a comparison of QN-302 and CX-5461, findings on S100P gene down-regulation, and anti-tumor activity of QN-302. QN-302 targets G-Quadruplex structures in various tumors, while QN-247 focuses on nucleolin-expressing cancers. Orphan Drug Designation for QN-302 in pancreatic cancer was granted in January 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.94%
Tags
conferences
-
Rhea-AI Summary

Qualigen Therapeutics has presented promising data at the AACR Special Conference on RAS, highlighting its novel small molecules targeting RAS in pancreatic and breast cancer models. The studies demonstrated significant anti-RAS activity, showing compounds that bind specifically to certain KRAS mutations, thereby inhibiting cancer cell growth. Chief Medical Officer Tariq Arshad emphasized the potential of these RAS-targeted compounds to improve therapeutic outcomes, particularly for cancers with high relapse rates. The RAS oncogene is implicated in a substantial portion of various cancers, presenting a significant medical need.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.91%
Tags
none
-
Rhea-AI Summary

Qualigen Therapeutics published significant findings in the journal Molecules, demonstrating that their lead compound QN-302 exhibits strong anti-tumor activity against pancreatic cancer cell lines. The study reveals QN-302 downregulates the S100P gene, associated with several cancers, suggesting its potential as a biomarker for treatment response in pancreatic cancer. The Chief Medical Officer emphasized that this publication reinforces the compound's therapeutic prospects. Pancreatic cancer remains a major health challenge, and Qualigen is advancing QN-302 towards IND application submission in the near future.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
none
Rhea-AI Summary

Qualigen Therapeutics (Nasdaq: QLGN) provided an update on its progress in 2022, highlighting significant achievements amidst macroeconomic challenges. The company is advancing its lead program, QN-302, a cancer treatment with Orphan Drug Designation for pancreatic cancer, aiming to file an IND application in the first half of 2023. Qualigen also emphasizes ongoing RAS discovery efforts, therapeutic partnerships, and funding strategies. Additionally, QN-247 shows promise in preclinical studies for Triple Negative Breast Cancer, while a focus on NanoSynex aims to enhance rapid antibiotic testing. Austerity measures have been implemented to extend cash runway through 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.85%
Tags
none

FAQ

What is the current stock price of Qualigen Therapeutics (QLGN)?

The current stock price of Qualigen Therapeutics (QLGN) is $4.04 as of December 23, 2024.

What is the market cap of Qualigen Therapeutics (QLGN)?

The market cap of Qualigen Therapeutics (QLGN) is approximately 2.9M.

What is Qualigen Therapeutics' core business?

Qualigen Therapeutics focuses on developing innovative treatments for adult and pediatric cancer through its advanced therapeutic programs.

What is QN-302?

QN-302 is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.

What recent achievements has Qualigen Therapeutics made?

Qualigen has transitioned to a clinical-stage company with the IND clearance for QN-302 and sold its FastPack® diagnostics business for $5 million.

What current projects is Qualigen involved in?

Qualigen is involved in early-phase clinical trials to validate the efficacy and safety of QN-302 and other pipeline candidates.

How does Qualigen support its financial condition?

Qualigen's financial health is supported by proceeds from the FastPack® diagnostics business sale, enabling continued investment in therapeutic projects.

Does Qualigen Therapeutics collaborate with other entities?

Yes, Qualigen partners with various research institutions and industry leaders to advance its drug development initiatives.

Where is Qualigen Therapeutics headquartered?

Qualigen Therapeutics is headquartered in Carlsbad, California.

What is the significance of the IND clearance for QN-302?

The IND clearance allows QN-302 to transition from preclinical to clinical-stage, marking a significant step in its development as a cancer treatment.

How can I get more information about Qualigen Therapeutics?

For more information, visit their website at www.qlgntx.com.

Who can I contact for investor relations queries?

You can contact Qualigen's investor relations at ir@qlgntx.com or call 760-530-6487.

Qualigen Therapeutics, Inc.

Nasdaq:QLGN

QLGN Rankings

QLGN Stock Data

2.89M
708.69k
3.77%
1.77%
2.84%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CALIFORNIA